The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of "“Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2024 |
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, Shinjini Sen, Priyanka Kumar, Madhurima Majumdar, Renesa Dasgupta, Sampurna Mukherjee, Shrimanti Das, Indrilla Ghose, Petr Pavek, Muruga Poopathi Raja Karuppiah, Anil A. Chuturgoon, Krishnan Anand. Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions, Bioconjugate Chemistry. 2024; 35: 1089. https://doi.org/10.1021/acs.bioconjchem.4c00253 |
|
2 |
2020 |
Robert I. Troup, Charlene Fallan, Matthias G. J. Baud. Current strategies for the design of PROTAC linkers: a critical review, Exploration of Targeted Anti-tumor Therapy. 2020; 1: https://doi.org/10.37349/etat.2020.00018 |
|
3 |
2021 |
Ota Fuchs, Radka Bokorova. Preclinical Studies of PROTACs in Hematological Malignancies, Cardiovascular & Hematological Disorders-Drug Targets. 2021; 21: 7. https://doi.org/10.2174/1871529X21666210308111546 |
|
4 |
2024 |
Rohini Pujari, Shvetank Bhatt, Urvashi Soni, Shreya Sharma, Shubham Patil. 2024; 67. https://doi.org/10.1007/978-981-97-5077-1_4 |
|
5 |
2021 |
Moritz Fürstenau, Barbara Eichhorst. Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance, Cancers. 2021; 13: 1336. https://doi.org/10.3390/cancers13061336 |
|
6 |
2022 |
Rachael Arthur, Alexander Wathen, Elizabeth A. Lemm, Freda K. Stevenson, Francesco Forconi, Adam J. Linley, Andrew J. Steele, Graham Packham, Beatriz Valle-Argos. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells, Cellular Signalling. 2022; 96: 110358110358. https://doi.org/10.1016/j.cellsig.2022.110358 |
|
7 |
2022 |
Jingyu Zhang, Jinxin Che, Xiaomin Luo, Mingfei Wu, Weijuan Kan, Yuheng Jin, Hanlin Wang, Ao Pang, Cong Li, Wenhai Huang, Shenxin Zeng, Weihao Zhuang, Yizhe Wu, Yongjin Xu, Yubo Zhou, Jia Li, Xiaowu Dong. Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton’s Tyrosine Kinase for the Treatment of Lymphoma, Journal of Medicinal Chemistry. 2022; 65: 9096. https://doi.org/10.1021/acs.jmedchem.2c00324 |
|
8 |
2023 |
Manvendra Kumar, Joydeep Chatterjee, Dimpy Rani, Raj Kumar. 2023; 117. https://doi.org/10.1016/B978-0-443-18616-5.00006-5 |
|
9 |
2024 |
Raffaele Sciaccotta, Sebastiano Gangemi, Giuseppa Penna, Laura Giordano, Giovanni Pioggia, Alessandro Allegra. Potential New Therapies “ROS-Based” in CLL: An Innovative Paradigm in the Induction of Tumor Cell Apoptosis, Antioxidants. 2024; 13: 475. https://doi.org/10.3390/antiox13040475 |
|
10 |
2022 |
Ota Fuchs, 2022; 71. https://doi.org/10.1016/B978-0-323-90042-3.15001-7 |
|
11 |
2023 |
Yi-Qian Li, William G. Lannigan, Shabnam Davoodi, Fereidoon Daryaee, Ana Corrionero, Patricia Alfonso, Jose A. Rodriguez-Santamaria, Nan Wang, John D. Haley, Peter J. Tonge. Discovery of Novel Bruton’s Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy, Journal of Medicinal Chemistry. 2023; 66: 7454. https://doi.org/10.1021/acs.jmedchem.3c00176 |
|
12 |
2023 |
Ana Portelinha, Hans-Guido Wendel. The cat-and-mouse game of BTK inhibition, Blood. 2023; 141: 1502. https://doi.org/10.1182/blood.2022018936 |
|
13 |
2022 |
Matthew R. Burke, Alexis R. Smith, Guangrong Zheng. Overcoming Cancer Drug Resistance Utilizing PROTAC Technology, Frontiers in Cell and Developmental Biology. 2022; 10: 872729. https://doi.org/10.3389/fcell.2022.872729 |
|
14 |
2023 |
Deyi Zhang, Hailey M. Harris, Jonathan Chen, Jen Judy, Gabriella James, Aileen Kelly, Joel McIntosh, Austin Tenn-McClellan, Eileen Ambing, Ying Siow Tan, Hao Lu, Stefan Gajewski, Matthew C. Clifton, Stephanie Yung, Daniel W. Robbins, Mehdi Pirooznia, Sigrid S. Skånland, Erika Gaglione, Maissa Mhibik, Chingiz Underbayev, Inhye E. Ahn, Clare Sun, Sarah E. M. Herman, Mark Noviski, Adrian Wiestner. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts, Blood. 2023; 141: 1584. https://doi.org/10.1182/blood.2022016934 |
|
15 |
2024 |
Ruxandra Moraru, Beatriz Valle-Argos, Annabel Minton, Lara Buermann, Suyin Pan, Thomas E. Wales, Raji E. Joseph, Amy H. Andreotti, Jonathan C. Strefford, Graham Packham, Matthias G. J. Baud. Exploring 2-Sulfonylpyrimidine Warheads as Acrylamide Surrogates for Targeted Covalent Inhibition: A BTK Story, Journal of Medicinal Chemistry. 2024; 67: 13572. https://doi.org/10.1021/acs.jmedchem.3c01927 |
|
16 |
2022 |
Guangyan Du, Jie Jiang, Nathaniel J. Henning, Nozhat Safaee, Eriko Koide, Radosław P. Nowak, Katherine A. Donovan, Hojong Yoon, Inchul You, Hong Yue, Nicholas A. Eleuteri, Zhixiang He, Zhengnian Li, Hubert T. Huang, Jianwei Che, Behnam Nabet, Tinghu Zhang, Eric S. Fischer, Nathanael S. Gray. Exploring the target scope of KEAP1 E3 ligase-based PROTACs, Cell Chemical Biology. 2022; 29: 1470. https://doi.org/10.1016/j.chembiol.2022.08.003 |
|
17 |
2025 |
Lihua Tan, Yanbei Tu, Zhimin Miao, Yuxin Zhao, Yongkai Liang, Jinmiao Zhong, Ruting Zhong, Nan Xu, Xin Chen, Chengwei He. Glycyrol alleviates osteoporosis through dual modulation on osteoclastogenesis and osteogenesis by targeting Syk signaling pathway, Phytomedicine. 2025; 138: 156429156429. https://doi.org/10.1016/j.phymed.2025.156429 |
|
18 |
2021 |
Joel O. Cresser-Brown, Graham P. Marsh, Hannah J. Maple. Reviewing the toolbox for degrader development in oncology, Current Opinion in Pharmacology. 2021; 59: 43. https://doi.org/10.1016/j.coph.2021.04.009 |